NCT00006034 arm group acdb1c7ce4d4f40c5caaddbffa76e2f1 [clinicaltrials_resource:NCT00006034/arm-group/acdb1c7ce4d4f40c5caaddbffa76e2f1]
NCT00006034 arm group acdb1c7ce4d4f40c5caaddbffa76e2f1 [clinicaltrials_resource:NCT00006034/arm-group/acdb1c7ce4d4f40c5caaddbffa76e2f1]
Bio2RDF identifier
NCT00006034/arm-group/acdb1c7ce4d4f40c5caaddbffa76e2f1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... db1c7ce4d4f40c5caaddbffa76e2f1
description [clinicaltrials_vocabulary:description]
Patients receive doxorubicin IV once weekly in weeks 1-6.
identifier
clinicaltrials_resource:NCT00006034/arm-group/acdb1c7ce4d4f40c5caaddbffa76e2f1
title
NCT00006034 arm group acdb1c7ce4d4f40c5caaddbffa76e2f1
@en
type
label
NCT00006034 arm group acdb1c7c ...... b1c7ce4d4f40c5caaddbffa76e2f1]
@en